Obesity: A review of currently used antiobesity drugs and new compounds in clinical development
by
Zieba R.
Zaklad Farmakodynamiki,
Uniwersytet Medyczny w Lodzi.
Postepy Hig Med Dosw (Online). 2007 Oct 19;61:612-26.


ABSTRACT

This review summarizes data on currently used antiobesity drugs and new compounds under clinical development. Three antiobesity drugs are currently accepted for long-term use. Sibutramine is a noradrenaline and serotonin reuptake inhibitor which reduces body weight by about 4-5 kg but increases heart rate and arterial blood pressure. Orlistat is a gastrointestinal lipase inhibitor which results in mean weight loss by about 3 kg and reduces the incidence of type 2 diabetes in patients with impaired glucose tolerance; however, adverse gastrointestinal effects have been observed. Rimonabant is an endocannabinoid CB1 receptor antagonist which induces a 4-5 kg mean weight loss and improves glycemic and lipid profiles, but it induces anxiety and depressive disorders. Unfortunately, there are no data on the chronic administration of these drugs. Other drugs can induce weight loss, e.g. some antidepressants, antiseizure agents, and antidiabetic drugs. The moderate efficacy of currently used antiobesity drugs has led to an intense effort to identify new, safe antiobesity drugs with better therapeutic profiles. The new antiobesity drugs under clinical development include: 1) agents that affect neurotransmitters in the central nervous system, including noradrenaline and dopamine reuptake inhibitors (bupropion, radafaxine), selective 5HT2C receptor agonists (lorcaserin), and selective 5HT6 receptor antagonists, 2) agents that modulate the activity of neuropeptides influencing food intake, including leptin analogues, human ciliary neurotrophic factor (Axokine), neuropeptide Y antagonists, and melanine-concentrating hormone antagonists, 3) agents that affect the peripheral satiety signals and brain-gut axis, e.g. selective cholecystokinin receptor A agonists, PYY3-36, agents decreasing ghrelin activity, 4) thermogenic agents, e.g. selective beta3 receptor agonists and selective thyroid hormone receptor beta agonists, and 5) others, e.g. human growth hormone fragment (AOD9604) and gastrointestinal lipase inhibitor (cetilistat).
Nutraceuticals
Nutrigenomics
Iron deficiency
DL-phenylalanine
Calcium and mood
Vitamins and mood
Docosahexaenoic acid
Catecholamine depletion
Bad moods and sick hearts
Ascorbic acid, mood, and sex
Functional foods and the GI tract


Go To Good Drug Guide
Refs
HOME
HedWeb
HerbWeb
erythroxylum-coca.com
BLTC Research
Superhappiness?
Amphetamines.com
Paradise-Engineering
The Abolitionist Project
The Hedonistic Imperative
MDMA/Ecstasy: Utopian Pharmacology